LTRN insider transaction filings
Lantern Pharma Inc. — 22 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-05-14. Screen LTRN transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-14 | 4 | Schalop Lee Troy — Director | Purchase (P): 48,544 @ $2.06 · Purchase (P): 48,544 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | KEYSER D JEFFREY — Director | Purchase (P): 48,544 @ $2.06 · Purchase (P): 48,544 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Silberstein David S. — Director | Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 17,307 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Schalop Lee Troy — Director | Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 18,460 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Chandru Vijay — Director | Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 17,307 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | KEYSER D JEFFREY — Director | Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 28,844 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Maccecchini Maria-Luisa — Director | Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 21,152 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | Margrave David R. — Chief Financial Officer | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | Bhatia Kishor G. — Chief Scientific Officer | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-09-23 | 4 | Chandru Vijay — Director | Disposition to issuer (D): 9,135 (derivative) @ $0 · Grant/award (A): 9,135 (derivative) @ $0 · Disposition to issuer (D): 3,200 (derivative) @ $0 · Grant/award (A): 3,200 (derivative) @ $0 | EDGAR |
| 2025-09-23 | 4 | Bhatia Kishor G. — Chief Scientific Officer | Disposition to issuer (D): 52,200 (derivative) @ $0 · Grant/award (A): 52,200 (derivative) @ $0 · Disposition to issuer (D): 17,400 (derivative) @ $0 · Grant/award (A): 17,400 (derivative) @ $0 | EDGAR |
| 2025-09-23 | 4 | Margrave David R. — Chief Financial Officer | Disposition to issuer (D): 78,300 (derivative) @ $0 · Grant/award (A): 78,300 (derivative) @ $0 · Disposition to issuer (D): 26,100 (derivative) @ $0 · Grant/award (A): 26,100 (derivative) @ $0 | EDGAR |
| 2025-09-23 | 4 | Silberstein David S. — Director | Disposition to issuer (D): 9,135 (derivative) @ $0 · Grant/award (A): 9,135 (derivative) @ $0 · Disposition to issuer (D): 3,200 (derivative) @ $0 · Grant/award (A): 3,200 (derivative) @ $0 | EDGAR |
| 2025-09-23 | 4 | KEYSER D JEFFREY — Director | Disposition to issuer (D): 9,135 (derivative) @ $0 · Grant/award (A): 9,135 (derivative) @ $0 · Disposition to issuer (D): 3,200 (derivative) @ $0 · Grant/award (A): 3,200 (derivative) @ $0 | EDGAR |
| 2025-09-23 | 4 | SHARMA PANNA — President & CEO, Director | Disposition to issuer (D): 76,628 (derivative) @ $0 · Grant/award (A): 76,628 (derivative) @ $0 | EDGAR |
| 2025-08-20 | 4 | Schalop Lee Troy — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Kreis Leslie W. — 10% owner Cavu Management, LP — 10% owner Cavu Advisors, LLC — 10% owner BP Directors, LP — 10% owner | Sale (S): 7,206 @ $3.09 · Sale (S): 12,319 @ $3.09 · Sale (S): 1,903 @ $3.09 · Sale (S): 14,218 @ $3.09 · Sale (S): 4,354 @ $3.09 | EDGAR |
| 2025-06-13 | 4 | Kreis Leslie W. — 10% owner Cavu Management, LP — 10% owner Cavu Advisors, LLC — 10% owner BP Directors, LP — 10% owner | Sale (S): 3 @ $3.40 · Sale (S): 171 @ $3.40 · Sale (S): 10,925 @ $3.38 · Sale (S): 5 @ $3.40 · Sale (S): 293 @ $3.40 · Sale (S): 18,678 @ $3.38 · +9 more | EDGAR |
| 2025-06-13 | 4 | Fletcher Aaron G.L. — 10% owner BIOS Fund I, LP — 10% owner BIOS Fund I QP, LP — 10% owner BIOS Fund II, LP — 10% owner BIOS Fund II QP, LP — 10% owner BIOS Fund II NT, LP — 10% owner Bios Equity Partners, LP — 10% owner Bios Equity Partners II, LP — 10% owner BIOS Capital Management, LP — 10% owner BIOS Advisors GP, LLC — 10% owner | Sale (S): 7,206 @ $3.09 · Sale (S): 12,319 @ $3.09 · Sale (S): 1,903 @ $3.09 · Sale (S): 14,218 @ $3.09 · Sale (S): 4,354 @ $3.09 | EDGAR |
| 2025-06-13 | 4 | Fletcher Aaron G.L. — 10% owner BIOS Fund I, LP — 10% owner BIOS Fund I QP, LP — 10% owner BIOS Fund II, LP — 10% owner BIOS Fund II QP, LP — 10% owner BIOS Fund II NT, LP — 10% owner Bios Equity Partners, LP — 10% owner Bios Equity Partners II, LP — 10% owner BIOS Capital Management, LP — 10% owner BIOS Advisors GP, LLC — 10% owner | Sale (S): 3 @ $3.40 · Sale (S): 171 @ $3.40 · Sale (S): 10,925 @ $3.38 · Sale (S): 5 @ $3.40 · Sale (S): 293 @ $3.40 · Sale (S): 18,678 @ $3.38 · +9 more | EDGAR |
| 2025-05-29 | 4 | Kreis Leslie W. — 10% owner Cavu Management, LP — 10% owner Cavu Advisors, LLC — 10% owner BP Directors, LP — 10% owner | Sale (S): 3,790 @ $3.05 · Sale (S): 2,702 @ $2.87 · Sale (S): 3,639 @ $3.03 · Sale (S): 6,479 @ $3.05 · Sale (S): 4,620 @ $2.87 · Sale (S): 6,221 @ $3.03 · +9 more | EDGAR |
| 2025-05-29 | 4 | Fletcher Aaron G.L. — 10% owner BIOS Fund I, LP — 10% owner BIOS Fund I QP, LP — 10% owner BIOS Fund II, LP — 10% owner BIOS Fund II QP, LP — 10% owner BIOS Fund II NT, LP — 10% owner Bios Equity Partners, LP — 10% owner Bios Equity Partners II, LP — 10% owner BIOS Capital Management, LP — 10% owner BIOS Advisors GP, LLC — 10% owner | Sale (S): 3,790 @ $3.05 · Sale (S): 2,702 @ $2.87 · Sale (S): 3,639 @ $3.03 · Sale (S): 6,479 @ $3.05 · Sale (S): 4,620 @ $2.87 · Sale (S): 6,221 @ $3.03 · +9 more | EDGAR |
Recent 8-K events — Lantern Pharma Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-02 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-10 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-23 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-23 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LTRN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →